The World Health Organisation (WHO) has recommended the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential.
About:
Dolutegravir (DTG), sold under the brand name Tivicay, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS.
Initial studies had highlighted a possible link between DTG and neural tube defects (birth defects of the brain and spinal cord) in infants born to women using the drug at the time of conception.
But new studies have shown that DTG is more effective, easier to take and has fewer side effects than alternative drugs. It also has a high genetic barrier to developing drug resistance, which is important, given the rising trend of resistance.
In 2019, 82 low- and middle-income countries reported to be transitioning to DTG-based HIV treatment. The new recommendations aim at helping more nations improve their HIV policies.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
